This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The Allergy Advocacy Association of Rochester, New York to participate in a legislative event on February 27 to advocate for the passage of school access to Epinephrine Act. State Senate bill S02210 and Assembly bill A2566 would authorize students with allergies to carry and self-administer prescribed epinephrine, and require schools to maintain a supply of epinephrine for emergency use on students who have undiagnosed allergies.
Rochester, NY (PRWEB) February 22, 2013
The Allergy Advocacy Association will be holding a legislative action event at the State Capitol building in Albany, New York on Wednesday, February 27, 2013 in the concourse nearest to the capitol entrance. The primary purpose of the event is to help pass the School Access to Epinephrine Act during this year’s session of the legislature. The law would authorize students with allergies to carry and self-administer prescribed epinephrine, and require schools to maintain a supply of epinephrine for emergency use on students who have undiagnosed allergies.
During the morning, Senators Senator Michael Ranzenhofer, Republican 61st District, Senator George Maziarz, Republican, 62nd District and Assemblyman Felix Ortiz, Democrat, 51st District, who are sponsors of bills relating to Epi-PenTM injectors in the NYS school systems, will make statements encouraging their colleagues to vote in favor of improved access to epinephrine. In the afternoon, meetings will take place with individual law makers in their offices. At the Allergy Advocacy Association exhibit booth petitions in support of this important legislation will be available for anyone to sign, and other valuable information will be provided to individuals with life-threatening allergies at risk for anaphylaxis. To help support this legislation, all are invited to attend the lobbying event in Albany and sign our petitions, contact your New York State representatives directly or log on to Allergy Advocacy Association.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10453528.htm